1. A systematic review of intravenous immunoglobulin for treatment of unexplained recurrent miscarriage 
Baris Ata, M.D., M.Sc., Seang Lin Tan, M.D., M.B.A., Fady Shehata, M.B., B.Ch., M.Sc., Hananel Holzer, M.D., William Buckett, M.D. 
Fertility and Sterility 
Volume 95, Issue 3, Pages e2 (March 2011)
DOI: /j.fertnstert
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
Live birth rate with IVIG in women with recurrent miscarriage.
Fertility and Sterility  , e2DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

3. Figure 2
Live birth rates stratified by type of miscarriage. (A) Primary recurrent miscarriage. (B) Secondary recurrent miscarriage.
Fertility and Sterility  , e2DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

4. Figure 3
Live birth rate stratified by treatment start time. (A) Before pregnancy. (B) After pregnancy.
Fertility and Sterility  , e2DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

5. Auxiliary analysis: live birth rate in women with secondary recurrent miscarriage, including trials recruiting women with antiphospholipid antibodies. Christiansen et al. (10) includes only women who had recurrent miscarriage after a prior live birth.
Fertility and Sterility  , e2DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

6. Auxiliary analysis: live birth rates in trials comparing IVIG and saline.
Fertility and Sterility  , e2DOI: ( /j.fertnstert )
Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions